Global Surge in AI-Driven Drug Discovery Collaborations Since 2026

　　【Pharmaceutical Network Industry Dynamics】The "Double Ten Rule" of traditional new drug development — a decade-long cycle and a billion-dollar investment — was once an iron law standing in the way of the biopharmaceuticals industry. However, with the deep involvement of artificial intelligence technology, this situation is expected to change. Some institutions have pointed out that AI models can reduce compound design time by 70% and increase R&D success rates tenfold. A revolution in drug development driven by AI has begun. In 2026, the trend of collaborations in the AI pharmaceuticals field will continue to surge.
 

Recently, Insilico Medicine reached a licensing and drug discovery collaboration with Eli Lilly. Both parties will leverage Insilico Medicine's AI-driven drug discovery capabilities to accelerate the discovery and development of novel therapies across multiple therapeutic areas. Under the agreement, Lilly secures an exclusive global license for the development, manufacturing, and commercialization of a preclinical-stage potential new oral therapy targeting specific indications. Additionally, combining Insilico’s advanced Pharma.AI platform with Lilly’s deep expertise in R&D and disease areas, Insilico Medicine and Lilly will collaborate on multiple research projects around targets selected by Lilly. The total value of this deal could reach up to approximately $2.75 billion. Furthermore, Insilico Medicine is also eligible to receive tiered royalties based on future sales.
 

The upgrade of Eli Lilly's collaboration from software licensing to in-depth R&D cooperation demonstrates that large multinational pharmaceutical companies (MNCs) are systematically integrating external AI technologies into their core R&D pipelines, with Insilico Medicine at the forefront of this trend.
 

Recently, Takeda Pharmaceutical, a multinational pharmaceutical company, officially entered into a multi-year, in-depth partnership agreement with AI biotech company Iambic Therapeutics. The collaboration focuses on the research and development of small molecule drugs in the fields of oncology, gastrointestinal diseases, and inflammation. By integrating Iambic's core artificial intelligence technology and fully automated wet lab capabilities, the two parties have initiated a new cooperative model of "pipeline synergy" in the AI-driven drug discovery sector. The total value of this transaction is up to $1.7 billion. According to the cooperation agreement disclosed by both parties, Takeda will obtain exclusive rights to Iambic’s core technology platform, NeuralPLexer. This platform significantly enhances the efficiency and accuracy of target selection and molecular design through its ability to predict protein and protein-ligand structures.
 

In addition, AstraZeneca and Tsinghua University recently signed a university-level scientific research cooperation agreement and jointly established the "Tsinghua University (Academy for Advanced Innovation in Intelligent Industries) - AstraZeneca Joint Research Center for AI-Driven Drug Discovery," focusing on core areas such as AI drug discovery, translational medicine, and clinical development to deepen collaboration and accelerate the translation of research achievements into clinical and practical applications.
 

Globally, leading pharmaceutical companies such as AstraZeneca, Pfizer, Johnson & Johnson, Sanofi, and Novartis have already established partnerships with AI enterprises. Meanwhile, pharmaceutical companies in China are also accelerating their adoption of AI technology, ushering in a golden era of development for the industry.
 

For example, XtalPi has successively announced collaborations with Dongyang Guangya Pharmaceutical, Qilu Pharmaceutical, Yaotang Biotech, and Iambic Therapeutics this year. Among them, Insilico Medicine reached a strategic cooperation totaling HKD 9.31 billion with Qilu Pharmaceutical, focusing on target development for cardiovascular metabolic diseases. Dongyang Guangya Pharmaceutical and XtalPi have established a joint venture, planning to invest hundreds of millions of yuan in jointly building “AI+Robot"Joint Laboratory."
 

Reportedly, Dongyang Guangya Pharmaceutical (HEC Pharm) and XtalPi will empower at the foundational level through AI + robotics technology to break the limitations of "data silos" in traditional pharmaceutical enterprises and the "high threshold" of AI algorithm development. They aim to comprehensively accelerate drug pipeline innovation and clinical translation with an automated and intelligent drug R&D engine. Meanwhile, HEC Pharm's unique high-quality data combined with XtalPi’s AI + robotics technology will jointly enhance the predictive accuracy and efficiency of AI models, creating a dual technical advantage of "data + algorithms." In the future, as the full lifecycle AI-driven drug discovery engine co-built by both parties becomes accessible to the industry, this collaboration is expected to expedite the transformation of the pharmaceutical R&D ecosystem. It will also pave the way for both parties to explore business models that convert data assets into AI products and "Model-as-a-Service" (MaaS).
 

Since 2026, the wave of global cooperation in the artificial intelligence (AI) pharmaceuticals sector has continued to surge, with dense instances of collaborative innovation between industry, academia, research, and Chinese and foreign pharmaceutical enterprises being implemented. The integration of artificial intelligence and biomedicine is entering a phase of large-scale application. From Insilico Medicine's $2.75 billion collaboration with Eli Lilly, to the intensive layout by companies within China, to the comprehensive adoption by global pharmaceutical enterprises, AI-driven pharmaceuticals are undergoing a critical leap from technological validation to industrial implementation. This revolution in drug development driven by artificial intelligence is not only breaking the traditional "double ten rule" of R&D but also reshaping the innovative ecosystem of the biopharmaceuticals industry. In the future, with the continuous iteration of AI technology and the deepening integration with the industry, AI pharmaceuticals will embrace broader development opportunities, propelling global pharmaceutical innovation into a new stage of development.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.